PureTech Health (LON:PRTC) Trading Up 13.4% - Should You Buy?

Key Points

• PureTech Health's shares surged by 13.4% during trading, reaching a last traded price of GBX 120.64 ($1.64) after closing at GBX 106.40 ($1.44).
• Insider Bharatt Chowrira purchased 167,739 shares at an average price of GBX 1 per share, demonstrating confidence in the company's stock.
• PureTech Health focuses on developing medicines for nervous, gastrointestinal, and immune system diseases, and is currently working on a microbiome immune system drug-discovery platform.

PureTech Health plc (LON:PRTC - Get Free Report) shares were up 13.4% during trading on Friday . The company traded as high as GBX 120.80 ($1.63) and last traded at GBX 120.64 ($1.63). Approximately 1,893,088 shares changed hands during mid-day trading, an increase of 155% from the average daily volume of 742,421 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Stock Performance

The firm has a market cap of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The stock's 50 day moving average is GBX 129.31 and its 200 day moving average is GBX 129.65. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82.

Insider Transactions at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of the business's stock in a transaction on Thursday, July 3rd. The stock was purchased at an average price of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by corporate insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.